Henmi S, Kashiwagi S, Matsuda H, Nishikawa M, et al. Clinical-Genomic Risk Discordance in Early HR+/HER2- Breast Cancer: A Real-World Cohort from Japan Demonstrates Treatment Impact of Oncotype DX. Anticancer Res 2026;46:439-446.
PMID: 41469107